PMID- 14579298
OWN - NLM
STAT- MEDLINE
DCOM- 20031118
LR  - 20061115
IS  - 0008-543X (Print)
IS  - 0008-543X (Linking)
VI  - 99
IP  - 5
DP  - 2003 Oct 25
TI  - HER-2/neu amplification by fluorescence in situ hybridization in cytologic 
      samples from distant metastatic sites of breast carcinoma.
PG  - 310-5
AB  - BACKGROUND: Amplification of the HER-2/neu oncogene has been proposed as a target 
      for antibody-based therapies and as a predictor of chemoresponsiveness in 
      advanced breast carcinoma. Few studies have concentrated on HER-2/neu gene 
      evaluation by fluorescence in situ hybridization (FISH) on distant metastatic 
      sites and none have been performed on cytologic samples. The current study 
      evaluated HER-2/neu amplification by FISH on cytologic samples obtained from 
      distant metastatic lesions of breast carcinoma to update HER-2/neu 
      characterization through a safe and easier procedure than biopsy. METHODS: 
      Twenty-two cytologic samples from distant metastases (12 hepatic samples, 4 skin 
      samples, 3 pleural samples, and 3 peritoneal samples) were submitted to HER-2/neu 
      evaluation by FISH. Seventeen corresponding primary breast tumors also were 
      evaluated by FISH on paraffin histologic sections or on destained archival 
      cytologic smears. RESULTS: Seven of the 22 metastases (32%) were amplified. 
      Amplification was observed in 4 of the 12 liver metastases, in 1of the 3 ascitic 
      fluid specimens, and in 2 of the 4 skin metastases. In all the three pleural 
      fluid specimens, HER-2/neu was unamplified. Matched results from primary and 
      metastatic lesions were obtained in 14 cases (5 were amplified and 9 were 
      unamplified on both primary and metastatic tumors). CONCLUSIONS: The results of 
      the current study emphasized the feasibility and advantages of two rapid and very 
      informative techniques, such as fine-needle aspiration biopsy and FISH. Both 
      procedures were performed to ascertain the malignant nature of a suspicious 
      lesion and to obtain predictive markers for response. Since the advent of 
      trastuzumab, the characterization of the molecular profile in metastatic breast 
      disease has become increasingly important for targeted therapy selection.
CI  - Copyright 2003 American Cancer Society.
FAU - Bozzetti, Cecilia
AU  - Bozzetti C
AD  - Department of Medical Oncology, University Hospital, Parma, Italy. 
      cbozzetti@ao.pr.it
FAU - Personeni, Nicola
AU  - Personeni N
FAU - Nizzoli, Rita
AU  - Nizzoli R
FAU - Guazzi, Annamaria
AU  - Guazzi A
FAU - Flora, Marcella
AU  - Flora M
FAU - Bassano, Cristina
AU  - Bassano C
FAU - Negri, Francesca
AU  - Negri F
FAU - Martella, Eugenia
AU  - Martella E
FAU - Naldi, Nadia
AU  - Naldi N
FAU - Franciosi, Vittorio
AU  - Franciosi V
FAU - Cascinu, Stefano
AU  - Cascinu S
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Cancer
JT  - Cancer
JID - 0374236
SB  - IM
MH  - Biopsy, Needle
MH  - Breast Neoplasms/*genetics/*pathology
MH  - Carcinoma/*genetics/*secondary
MH  - Culture Techniques
MH  - Female
MH  - Gene Amplification
MH  - *Genes, erbB-2
MH  - Humans
MH  - *In Situ Hybridization, Fluorescence
MH  - Liver Neoplasms/genetics/secondary
MH  - Peritoneal Neoplasms/genetics/secondary
MH  - Pleural Neoplasms/genetics/secondary
MH  - Prognosis
MH  - Sampling Studies
MH  - Sensitivity and Specificity
MH  - Skin Neoplasms/genetics/secondary
EDAT- 2003/10/28 05:00
MHDA- 2003/12/03 05:00
CRDT- 2003/10/28 05:00
PHST- 2003/10/28 05:00 [pubmed]
PHST- 2003/12/03 05:00 [medline]
PHST- 2003/10/28 05:00 [entrez]
AID - 10.1002/cncr.11731 [doi]
PST - ppublish
SO  - Cancer. 2003 Oct 25;99(5):310-5. doi: 10.1002/cncr.11731.